Everything you need to know about TMS for Multiple Sclerosis: Addressing Fatigue, Depression, and Cognitive Impairment — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Multiple sclerosis (MS) is an autoimmune demyelinating disease affecting approximately 2.8 million people worldwide. While disease-modifying therapies have revolutionized treatment of the underlying inflammatory process, many MS patients continue to struggle with symptoms that these medications do not directly address: debilitating fatigue, depression, cognitive impairment, and spasticity. Transcranial magnetic stimulation offers a non-invasive approach to targeting these secondary symptoms, potentially improving quality of life for patients who have inadequate relief from existing treatments.

What You’ll Learn

• How MS-related fatigue, depression, and cognitive impairment differ from primary symptoms
• Which brain targets are used for different MS symptoms (DLPFC vs. motor cortex)
• What research shows about TMS response rates for MS-related symptoms
• How TMS for MS fits into a comprehensive rehabilitation program
• Practical considerations MS patients should know before starting TMS

Understanding MS-Related Symptoms

The symptoms of MS arise from both inflammatory demyelination and neurodegenerative processes that disrupt neural signal transmission. Lesions can occur throughout the brain and spinal cord, producing varied symptoms depending on location.

Fatigue is the most common and often most disabling symptom of MS, affecting up to 80% of patients. MS fatigue is distinct from ordinary tiredness: it is often disproportionate to activity level, worsens with heat, and may not improve with rest. The mechanisms are multifactorial, involving:

• Disconnection of cortical and subcortical networks
• Increased metabolic demand from demyelinated axons
• Inflammatory cytokines affecting CNS function
• Depression-related fatigue

Cognitive impairment affects 40-65% of MS patients and can involve problems with processing speed, working memory, executive function, and attention. These deficits result from both white matter lesions disrupting network connectivity and gray matter atrophy.

Depression is three times more common in MS than in the general population. While psychological reactions to chronic illness contribute, MS depression also reflects the neurobiological impact of CNS lesions on mood-regulating circuits.

How TMS Addresses MS Symptoms

TMS can potentially improve MS-related symptoms through several mechanisms:

Enhancing cortical excitability and network connectivity: Demyelination disrupts the timing and efficiency of neural signaling. TMS may enhance synaptic plasticity and strengthen surviving connections, partially compensating for lost white matter integrity.

Reducing cortical hyperexcitability: Paradoxically, some MS patients show cortical hyperexcitability, particularly in motor cortex, contributing to spasticity and abnormal reflexes. Low-frequency TMS may normalize this hyperexcitability.

Modulating neuroinflammation: Emerging evidence suggests TMS may have anti-inflammatory effects, reducing pro-inflammatory cytokines that contribute to fatigue and mood symptoms.

Targeting specific circuits: Depending on the symptom, different cortical targets may be appropriate.

Evidence for TMS in MS Fatigue

MS fatigue has been the most extensively studied application of TMS in MS. Several randomized controlled trials have demonstrated benefits:

A 2019 study in Multiple Sclerosis Journal randomized 30 MS patients with severe fatigue to active or sham TMS targeting the motor cortex. After 10 daily sessions, the active TMS group showed significant improvements on the Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS), with benefits persisting at 4-week follow-up.

Another study compared high-frequency (10 Hz) left DLPFC TMS versus motor cortex stimulation for MS fatigue. Both targets produced significant improvements, but DLPFC stimulation was superior for overall fatigue impact while motor cortex stimulation was better for physical fatigue symptoms.

The mechanisms may differ by target: DLPFC TMS may address fatigue related to depression and cognitive load, while motor cortex TMS may normalize the motor network dysfunction that contributes to physical fatigue.

TMS for MS-Related Depression

Depression in MS often responds poorly to standard antidepressants, possibly because of the neurobiological complexity of MS-related mood symptoms. TMS offers a targeted approach that bypasses some of these challenges.

Studies of TMS for MS depression have shown:

• Response rates of 40-60% in treatment-resistant patients
• Improvements in both depression and anxiety scores
• Reduction in fatigue independent of depression improvement
• Good tolerability with no worsening of MS symptoms

The left DLPFC is the standard target for TMS depression, using high-frequency (10 Hz) or theta burst protocols.

Cognitive Impairment in MS

Cognitive rehabilitation combined with TMS has shown promise for MS-related cognitive deficits. The approach involves stimulating regions involved in cognitive networks (DLPFC, parietal cortex) while patients engage in cognitive training tasks.

A 2021 pilot study found that 20 sessions of high-frequency DLPFC TMS combined with computerized cognitive training produced significant improvements in processing speed (as measured by the Symbol Digit Modalities Test) and working memory compared to cognitive training alone.

The combination approach may be particularly effective because TMS enhances neuroplasticity, potentially making the brain more responsive to cognitive rehabilitation.

Spasticity and Motor Symptoms

MS-related spasticity results from disruption of the corticospinal tract, leading to excessive stretch reflex activity and muscle stiffness. This can cause pain, limit mobility, and significantly impact quality of life.

Low-frequency TMS over the motor cortex may reduce spasticity by decreasing cortical excitability and normalizing the balance between excitatory and inhibitory inputs to motor neurons.

Studies have shown modest improvements in spasticity scores (Modified Ashworth Scale) following TMS, though the effects may be less dramatic than for other symptoms.

Treatment Protocols

TMS for MS typically involves:

1. Comprehensive symptom assessment to identify primary treatment targets
2. Motor threshold determination (may be elevated in MS due to corticospinal tract dysfunction)
3. Target selection based on symptoms:
   • Left DLPFC for fatigue, depression, and cognitive impairment
   • Motor cortex for physical fatigue and spasticity
   • Bilateral targets for complex presentations
4. Protocol selection — typically 10-20 daily sessions
5. Maintenance planning — weekly or biweekly sessions to sustain benefits

Practical Considerations for MS Patients

MS patients considering TMS should be aware of several factors:

• Cognitive impairment may affect ability to consent or cooperate with treatment
• Fatigue is often worsened immediately after TMS sessions; scheduling later in the day may be helpful
• Heat sensitivity — MS symptoms may worsen with increased body temperature during or after TMS
• Disease-modifying therapies do not interact with TMS
• Comorbidities such as seizures or significant brain atrophy may affect candidacy

The Bottom Line

TMS offers a valuable option for MS patients struggling with fatigue, depression, or cognitive impairment that has not responded adequately to standard treatments. While not a cure for MS, it can meaningfully improve quality of life by targeting symptoms that disease-modifying therapies do not address.

As research continues, TMS may become increasingly integrated into comprehensive MS rehabilitation programs, offering hope for improved function and well-being.

If you have MS and are experiencing persistent fatigue, depression, or cognitive symptoms, discuss TMS with your neurologist to determine whether you may be a candidate. Look for clinics with experience treating MS patients with neuromodulation.